Results 171 to 180 of about 6,012,951 (335)

Comparative Transcriptional Profiling of Key Macrophage and Fibroblast Subpopulations in Rheumatoid Arthritis–Associated Lung Disease

Arthritis &Rheumatology, EarlyView.
Objective Rheumatoid arthritis (RA) often involves extra‐articular complications, including interstitial lung disease (ILD) and/or pulmonary nodules. Transcriptomic profiling of lung tissue provides the opportunity to directly assess cell‐specific gene expression and corresponding pathway activation in different types of rheumatoid lung disease ...
Tracy Tabib, Ogechukwu Ezenwa, Joshua Sciurba, Eleanor B. Valenzi, John Sembrat, Brittany Cody, Jishnu Das, Robert Lafyatis, Dana P. Ascherman   +8 more
wiley   +1 more source

SGLT2 Inhibition as a Novel Therapeutic Strategy in Rheumatic Heart Disease. [PDF]

JACC Asia
Morel O, Mai AT, Zühlke L, Jouven X, Marchandot B, Pressman G, Patton-Bolman C, Roffi M, Pibarot P.   +8 more
europepmc   +1 more source

RHEUMATISM AND HEART DISEASE

American Journal of Public Health and the Nations Health, 1928
openaire   +3 more sources

Market landscape of penicillin for syphilis and rheumatic heart disease, WHO South-East Asia Region

Gereltuya Dorj, Uhjin Kim, Polin Chan, Pradeep Joshi, Abhishek Royal, Karina Razali   +5 more
openalex   +1 more source

Surveillance and evaluation data resource guide for heart disease and stroke prevention programs [PDF]

High blood pressure, high sodium intake, high cholesterol, and smoking continue to put more people at risk of heart disease and stroke. To address these risk factors, the CDC focuses on the ABCS of heart disease and stroke prevention\u2014appropriate ...

core  

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo‐Controlled Phase 3 Trials

Arthritis &Rheumatology, EarlyView.
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf, Puja P. Khanna, Milan Petronijevic, Mamuka Lortkipanidze, Anand Patel, Kwabena Ayesu, Michael H. Pillinger, Atul Singhal, Joanna Sobierska, Jacquie Christie, Peter Traber, Rehan Azeem, Wesley DeHaan, Hugues Santin‐Janin, Bhavisha Desai, Alan Kivitz   +15 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Training pathways for task-shared point-of-care ultrasound for rheumatic heart disease screening and other conditions: a scoping review

Babalwa Zani, Laylah Ryklief, Scott Wirth, Doreen Nakagaayi, M Garcia Pardo, Andrea Beaton   +5 more
openalex   +2 more sources

Effect of Colchicine on Left Atrial Mechanics in Rheumatic Heart Disease: The COL-RHD A Pilot Trial. [PDF]

JACC Asia
Gupta MD, Goel V, Mp G, Mahajan B, Bansal A, Batra V, Yusuf J, Shami M, Khanna R, Ramakrishnan S, Sharma M, Bhatt DL.   +11 more
europepmc   +1 more source

Mechanisms underlying rheumatic heart disease immune-mediated pathogenesis: T-cell responses, cytokine networks, and immune dysregulation as drivers of valvular injury

Adrien Lupieri, Juan Manuel Garrido Díaz, Thayse Batista Moreira, Adriana Jacauna, John K McCormick, Victor Nizet, Robert A. Levine, Elena Aikawa, Walderez O. Dutra, Walderez O. Dutra, Elena Aïkawa, P Chillo, Jacob P. Dal‐Bianco, Ayelet David, Richard R. Drake, Walderez O. Dutra, Walderez O. Dutra, David J. Gonzalez, Shiela Klassen, Bhagawam Koirala, Hakho Lee, Robert A Levine, John K McCormick, Dorah Nampijja, Victor Nizet, Russell A. Norris, Maria Carmo Pereira Nunes   +26 more
openalex   +1 more source